PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Reslizumab in Eosinophilic Asthma: A Review.

Abstract Reslizumab (Cinqaero(®); Cinqair(®)) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme. In three double-blind BREATH studies of up to 52 weeks' duration, adding intravenous reslizumab (3 mg/kg, once every 4 weeks) to the current asthma therapy of patients (aged 12-75 years) with eosinophilic asthma inadequately controlled with inhaled corticosteroids resulted in significant reductions in clinical asthma exacerbation frequency and significant improvements in lung function, asthma control and health-related quality of life relative to adding placebo. Pooled data from the two trials of 52 weeks' duration indicated similar benefits with reslizumab across various patient subgroups, including patients with severe eosinophilic asthma. Reslizumab was generally well tolerated, with very few recipients experiencing severe or serious treatment-related adverse events. Moreover, in an open-label extension study, continued use of reslizumab for up to 2 years was associated with durable lung function benefit, without any new tolerability concerns. Thus, intravenous reslizumab extends the valuable add-on treatment options for adults with severe eosinophilic asthma inadequately controlled with standard therapies.
PMID
Related Publications

Reslizumab (Cinqair) for severe eosinophilic asthma.

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Mepolizumab: A Review in Eosinophilic Asthma.

The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.

Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.

Authors

Mayor MeshTerms
Keywords
Journal Title drugs
Publication Year Start




PMID- 28421429
OWN - NLM
STAT- MEDLINE
DA  - 20170419
DCOM- 20170515
LR  - 20170515
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 77
IP  - 7
DP  - 2017 May
TI  - Reslizumab in Eosinophilic Asthma: A Review.
PG  - 777-784
LID - 10.1007/s40265-017-0740-2 [doi]
AB  - Reslizumab (Cinqaero(R); Cinqair(R)) is a humanized monoclonal antibody against
      interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation.
      Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in 
      adults, on the basis of data from the BREATH phase III clinical trial programme. 
      In three double-blind BREATH studies of up to 52 weeks' duration, adding
      intravenous reslizumab (3 mg/kg, once every 4 weeks) to the current asthma
      therapy of patients (aged 12-75 years) with eosinophilic asthma inadequately
      controlled with inhaled corticosteroids resulted in significant reductions in
      clinical asthma exacerbation frequency and significant improvements in lung
      function, asthma control and health-related quality of life relative to adding
      placebo. Pooled data from the two trials of 52 weeks' duration indicated similar 
      benefits with reslizumab across various patient subgroups, including patients
      with severe eosinophilic asthma. Reslizumab was generally well tolerated, with
      very few recipients experiencing severe or serious treatment-related adverse
      events. Moreover, in an open-label extension study, continued use of reslizumab
      for up to 2 years was associated with durable lung function benefit, without any 
      new tolerability concerns. Thus, intravenous reslizumab extends the valuable
      add-on treatment options for adults with severe eosinophilic asthma inadequately 
      controlled with standard therapies.
FAU - Deeks, Emma D
AU  - Deeks ED
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
      [email protected]
FAU - Brusselle, Guy
AU  - Brusselle G
AD  - Department of Respiratory Medicine, Ghent University Hospital and Ghent
      University, Ghent, Belgium.
AD  - Department of Epidemiology and Respiratory Medicine, Erasmus MC, Rotterdam, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 35A26E427H (reslizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Asthmatic Agents/administration & dosage/adverse
      effects/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse
      effects/pharmacokinetics/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Child
MH  - Humans
MH  - Middle Aged
MH  - Pulmonary Eosinophilia/*drug therapy
MH  - Quality of Life
MH  - Young Adult
EDAT- 2017/04/20 06:00
MHDA- 2017/05/16 06:00
CRDT- 2017/04/20 06:00
AID - 10.1007/s40265-017-0740-2 [doi]
AID - 10.1007/s40265-017-0740-2 [pii]
PST - ppublish
SO  - Drugs. 2017 May;77(7):777-784. doi: 10.1007/s40265-017-0740-2.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>